Dr. Scarpato on NMIBC: “We need more biomarkers”
“In non–muscle-invasive bladder cancer, we need more biomarkers, something that can hopefully reduce the frequency of invasive procedures for these patients,” says Kristen Scarpato, MD, MPH.
In this video, Kristen Scarpato, MD, MPH, discusses what is being done to improve the treatment options for patients with non–muscle-invasive bladder cancer, including what she does in her own practice. These ideas were focused on in a case-based discussion on intermediate-risk non–muscle-invasive bladder cancer that took place during the 2021 Society of Urologic Oncology Annual Meeting. Scarpato is an associate professor, residency program director, and vice chair of education in the department of urology at the Vanderbilt University Medical Center in Nashville, Tennessee.
Bundled payment program covers kidney stone care
July 22nd 2024"One day, we're going to have to move away from fee for service, so we'd be wise to try to navigate those waters ahead of time, so we're not left dealing with the aftermath when someone else has implemented it for us," says Ruchika Talwar, MD.
Grant to fund research on biomarkers for toxicity from prostate cancer radiation
July 11th 2024“By understanding the mirSNP genetic markers that predispose patients to adverse side effects from cancer therapy we can tailor these therapies to minimize harm and maximize efficacy," says Joanne B. Weidhaas, MD, PhD, MS.
